Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics : to Host Conference Call

06/15/2021 | 07:48am EST

Announcing Positive Phase 3 Results for Zuranolone, an Investigational Two-Week, Once Daily Therapeutic Being Evaluated for Major Depressive Disorder

Webcast scheduled for 8:00a.m. ET on Tuesday, June 15

Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast this morning, June 15, 2021 at 8:00 a.m. ET to review topline results from the Phase 3 WATERFALL Study evaluating zuranolone for major depressive disorder.

The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.


ę Business Wire 2021
All news about SAGE THERAPEUTICS, INC.
01/10SAGE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
01/06Needham Adjusts Sage Therapeutics Price Target to $85 From $79, Reiterates Buy Rating
MT
01/04Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tu..
BU
2021SVB Leerink Adjusts Sage Therapeutics PT to $60 From $70, Maintains Market Perform Rati..
MT
2021Sage Therapeutics Third Annual FutureCast Showcases Data from All Three Brain Health Fr..
AQ
2021Sage Therapeutics' Third Annual FutureCast Showcases Data from All Three Brain Health F..
BU
2021Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Developm..
AQ
2021Sage Therapeutics, Biogen Report Positive Data From Antidepressant Drug Candidate Zuran..
MT
2021SAGE THERAPEUTICS : and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the On..
PU
2021SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 6,65 M - -
Net income 2021 -458 M - -
Net cash 2021 1 433 M - -
P/E ratio 2021 -5,50x
Yield 2021 -
Capitalization 2 529 M 2 529 M -
EV / Sales 2021 165x
EV / Sales 2022 23,2x
Nbr of Employees 298
Free-Float 87,6%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 42,93 $
Average target price 73,05 $
Spread / Average Target 70,2%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
Amy Schacterle Senior VP-Research & Development Strategy
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.0.92%2 529
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338